Patents by Inventor Thale Jarvis

Thale Jarvis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antimycobacterial heterocyclic amides
    Patent number: 11655225
    Abstract: The present invention provides novel heterocylic amide compounds having useful antimycobacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 23, 2023
    Assignee: CRESTONE, INC.
    Inventors: Joshua Day, James Graham, Thale Jarvis, Elizabeth Mcfaddin, Urs Ochsner, Xicheng Sun, Christina Wong
  • Lung cancer biomarkers and uses thereof
    Patent number: 11221340
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: January 11, 2022
    Assignee: SomaLogic, Inc.
    Inventors: Sheri K. Wilcox, Deborah Ayers, Nebojsa Janjic, Larry Gold, Michael Riel-Mehan, Thale Jarvis
  • Lung Cancer Biomarkers and Uses Thereof
    Publication number: 20180275143
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
    Type: Application
    Filed: May 30, 2018
    Publication date: September 27, 2018
    Inventors: Sheri K. Wilcox, Deborah Ayers, Nebojsa Janjic, Larry Gold, Michael Riel-Mehan, Thale Jarvis
  • Antibacteriall heterocyclic ureas
    Patent number: 8716320
    Abstract: The present invention provides novel heterocyclic urea compounds having useful antibacterial activity, pharmaceutical compositions comprising one or more of these compounds, methods of making the same, and methods of using the same.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: May 6, 2014
    Assignee: Replidyne, Inc.
    Inventors: Joseph Guiles, Thale Jarvis, Sarah Strong, Xicheng Sun
  • Lung Cancer Biomarkers and Uses Thereof
    Publication number: 20130116150
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
    Type: Application
    Filed: July 11, 2011
    Publication date: May 9, 2013
    Applicant: SOMALOGIC, INC.
    Inventors: Sheri Wilcox, Deborah Ayers, Nebojsa Janjic, Larry Gold, Michael Riel-Mehan, Thale Jarvis
  • Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds
    Patent number: 8293919
    Abstract: The present invention provides novel sulfone and sulfoxide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and methods of production are provided.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: October 23, 2012
    Assignee: Crestone, Inc.
    Inventors: Joseph Guiles, Thale Jarvis, Sarah Strong, Xicheng Sun, Jian Qiu, John C. Rohloff
  • Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
    Patent number: 8148380
    Abstract: The present invention provides novel amide and sulfonamide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: April 3, 2012
    Assignee: Crestone, Inc.
    Inventors: Joseph Guiles, Thale Jarvis, Sarah Strong, Xicheng Sun, Jian Qiu, John C. Rohloff
  • Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds
    Publication number: 20120015941
    Abstract: The present invention provides novel amide and sulfonamide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.
    Type: Application
    Filed: July 23, 2008
    Publication date: January 19, 2012
    Applicant: CRESTONE, INC.
    Inventors: Joseph Guiles, Thale Jarvis, Sarah Strong, Xicheng Sun, Jian Qiu, John C. Rohloff
  • Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds
    Publication number: 20100286169
    Abstract: The present invention provides novel sulfone and sulfoxide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and methods of production are provided.
    Type: Application
    Filed: July 23, 2008
    Publication date: November 11, 2010
    Applicant: CRESTONE, INC.
    Inventors: Joseph Guiles, Thale Jarvis, Sarah Strong, Xicheng Sun, Jian Qiu, John C. Rohloff
  • Antibacterial heterocyclic ureas
    Publication number: 20080207703
    Abstract: The present invention provides novel heterocyclic urea compounds having useful antibacterial activity, pharmaceutical compositions comprising one or more of these compounds, methods of making the same, and methods of using the same.
    Type: Application
    Filed: July 23, 2007
    Publication date: August 28, 2008
    Applicant: Replidyne, Inc.
    Inventors: Joseph Guiles, Thale Jarvis, Sarah Strong, Xicheng Sun
  • Chemically modified double stranded nucleic acid molecules
    Publication number: 20050176018
    Abstract: This invention relates to novel chemically-modified nucleic acid molecules having specified formulae that exhibit increased resistance to nucleases and increased binding affinity to target nucleic acid molecules. The invention further relates to methods of modulating gene expression using the novel chemically modified nucleic acid molecules, and compositions and cells comprising said molecules.
    Type: Application
    Filed: November 17, 2003
    Publication date: August 11, 2005
    Applicant: Sirna Therapeutics, Inc.
    Inventors: James Thompson, Leonid Beigelman, James McSwiggen, Alexander Karpeisky, Laurent Bellon, Mark Reynolds, Michael Zwick, Thale Jarvis, Tod Woolf, Peter Haeberli, Jasenka Matulic-Adamic
  • Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
    Publication number: 20050074760
    Abstract: An enzymatic nucleic acid molecule comprising a 5?- and/or a 3?-cap structure, wherein said structure is not a 5?-5?-linked inverted nucleotide or a 3?-3?-linked inverted nucleotide.
    Type: Application
    Filed: May 6, 2003
    Publication date: April 7, 2005
    Inventors: Jasenka Matulic-Adamic, Leonid Beigelman, Alexander Karpeisky, Thale Jarvis, Nassim Usman, Anthony DiRenzo, Francine Wincott
  • Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
    Patent number: 6673611
    Abstract: This invention relates to novel chemically-modified nucleic acid molecules having specific formulae that exhibit increased resistance to nucleases and increased binding affinity to target nucleic acid molecules. The invention further relates to methods of modulating gene expression using the novel chemically modified nucleic acid molecules, and compositions and cells comprising said molecules.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: January 6, 2004
    Assignee: Sirna Therapeutics, Inc.
    Inventors: James Thompson, Leonid Beigelman, James McSwiggen, Alexander Karpeisky, Laurent Bellon, Mark Reynolds, Michael Zwick, Thale Jarvis, Tod Woolf, Peter Haeberli, Jasenka Matulic-Adamic
  • Method and reagent for the induction of graft tolerance and reversal of immune responses
    Publication number: 20030207837
    Abstract: The present invention relates to nucleic acid molecules which block synthesis and/or expression of an mRNA encoding B7-1, B7-2, B7-3 and/or CD40.
    Type: Application
    Filed: May 19, 2003
    Publication date: November 6, 2003
    Applicant: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Thale Jarvis, James McSwiggen
  • Method and reagent for the inhibition of grid
    Publication number: 20030134806
    Abstract: The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and antisense, which modulate the expression of the GRID (Grb2-related with Insert Domain) gene.
    Type: Application
    Filed: February 23, 2001
    Publication date: July 17, 2003
    Inventors: Thale Jarvis, Ira Von Carlowitz, James McSwiggen, Paul Andrew Hamblin, Jonathon Henry Ellis
  • Enzymatic nucleic acids containing 5?-and or 3?-cap structures
    Patent number: 6586238
    Abstract: An enzymatic nucleic acid molecule comprising a 5′- and/or a 3′-cap structure, wherein said structure is not a 5′-5′-linked inverted nucleotide or a 3′-3′-linked inverted nucleotide.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: July 1, 2003
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Jasenka Matulic-Adamic, Leonid Beigelman, Alexander Karpeisky, Thale Jarvis, Nassim Usman, Anthony DiRenzo, Francine Wincott
  • Method and reagent for the inhibition of checkpoint kinase-1 (Chk1) enzyme
    Publication number: 20030087847
    Abstract: The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and antisense, which modulate the expression of the Chk-1 gene.
    Type: Application
    Filed: February 2, 2001
    Publication date: May 8, 2003
    Applicant: Onyx Pharmaceuticals, Inc.
    Inventors: Thale Jarvis, James McSwiggen, Robert N. Booher, Patricia S. Holman, Ali R. Fattaey
  • Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
    Publication number: 20020142980
    Abstract: The invention features nucleic acid molecules with novel combinations of chemical modifications which are able to modulate gene expression.
    Type: Application
    Filed: May 25, 2001
    Publication date: October 3, 2002
    Inventors: James Thompson, Leonid Beigelman, James McSwiggen, Alexander Karpeisky, Laurent Bellon, Mark Reynolds, Michael Zwick, Thale Jarvis, Tod Woolf, Peter Haeberli, Jasenka Matulic-Adamic
  • Conjugates of a particle vector and oligonucleotides, process for their preparation, and pharmaceutical compositions containing them
    Patent number: 6214621
    Abstract: The invention relates to an ionic conjugate, which is stable in a biological medium, and which is comprised of a particle vector with at least one cationic, nonliquid, hydrophilic nucleus and of polyanionic oligonucleotides. The invention further concerns the pharmaceutical compositions containing these conjugates and the use of a particle vector to carry the oligonucleotides to the cells.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: April 10, 2001
    Assignee: Biovector Therapeutics, S.A.
    Inventors: Didier Betbeder, Roger Kravtzoff, Ignacio de Miguel, Sophie Sixou, Pamela Pavco, Thale Jarvis
  • Nucleic acid based inhibition of CD40
    Patent number: 6194150
    Abstract: Nucleic acid molecule which blocks synthesis and/or expression of an mRNA encoding B7-1, B7-2, B7-3 and/or CD40.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: February 27, 2001
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Thale Jarvis, James McSwiggen